Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

35.03USD
23 Oct 2014
Price Change (% chg)

$2.76 (+8.55%)
Prev Close
$32.27
Open
$32.70
Day's High
$35.44
Day's Low
$32.57
Volume
1,131,111
Avg. Vol
702,786
52-wk High
$39.94
52-wk Low
$27.51

ACOR.O

Chart for ACOR.O

About

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system.... (more)

Overall

Beta: 1.37
Market Cap (Mil.): $1,347.11
Shares Outstanding (Mil.): 41.74
Dividend: --
Yield (%): --

Financials

  ACOR.O Industry Sector
P/E (TTM): 71.37 152.31 33.65
EPS (TTM): 0.45 -- --
ROI: 2.87 -1.40 17.48
ROE: 4.21 -6.49 18.31
Search Stocks

Deals of the day- Mergers and acquisitions

(Adds Lindt & Spruengli, Yildiz Holding, Chiquita, Cisco, BASF SE, Actavis, Tibco, Discovery Communications Inc, Acorda Therapeutics)

24 Sep 2014

Acorda buys Civitas to gain access to Parkinson's drug

- Acorda Therapeutics Inc said it bought privately held Civitas Therapeutics for $525 million to gain access to a Parkinson's disease drug in late-stage development.

24 Sep 2014

UPDATE 2-Acorda buys Civitas to gain access to Parkinson's drug

(Adds comments from conference call, updates share movement)

24 Sep 2014

Acorda buys Civitas to gain access to Parkinson's drug

Sept 24 - Biotechnology company Acorda Therapeutics Inc said it bought privately held Civitas Therapeutics for $525 million to gain access to a Parkinson's disease drug in late development.

24 Sep 2014

Acorda Therapeutics says FDA rejects epilepsy drug

- Acorda Therapeutics Inc said the Food and Drug Administration rejected its nasal form of the current standard therapy for epilepsy patients who experience repetitive seizures.

02 May 2014

UPDATE 1-Acorda Therapeutics says FDA rejects epilepsy drug

* Shares fall about 11 pct (Adds analysts' comment, details, shares)

02 May 2014

Acorda Therapeutics says FDA rejects epilepsy drug

May 2 - Acorda Therapeutics Inc said the U.S. Food and Drug Administration rejected its nasal spray to treat epilepsy patients who experience repetitive seizures.

02 May 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks